Reports Q3 revenue $239.46M, consensus $222.68M. “Our exceptional performance this quarter highlights the continued strength of WAKIX and significant market opportunity that remains ahead. I am incredibly proud of our team’s focus and executional excellence, as we delivered very strong results today, which positions Harmony for future growth,” said Jeffrey Dayno, President and CEO of Harmony Biosciences (HRMY). “I continue to have firm conviction in our late-stage pipeline to deliver multiple catalysts over the next several years and, given our strong cash position, we intend to strategically pursue value-enhancing assets to add to our pipeline and build a broader product portfolio of innovative treatments that can help even more patients living with unmet medical needs.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Is HRMY a Buy, Before Earnings?
- Harmony Biosciences price target raised to $36 from $35 at Mizuho
- Harmony Biosciences Holdings: Strong Financial Performance and Promising Pipeline Drive Buy Rating
- Harmony Biosciences Holdings: Strong Financial Performance and Positive Outlook Drive Buy Rating
- Harmony Biosciences raises FY25 revenue view to $845M-$865M from $820M-$860M